E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
primary biliary cholangitis |
|
E.1.1.1 | Medical condition in easily understood language |
Primary biliary cholangitis is a rare chronic liver disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 27.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10080429 |
E.1.2 | Term | Primary biliary cholangitis |
E.1.2 | System Organ Class | 10019805 - Hepatobiliary disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of two doses of norucholic acid vs. placebo for the treatment of primary biliary cholangitis (PBC) in patients with an inadequate response to ursodeoxycholic acid (UDCA). |
|
E.2.2 | Secondary objectives of the trial |
To identify efficacious norucholic acid dose(s) for the treatment of PBC for further evaluation in phase III, To study safety and tolerability (adverse events, laboratory parameters) of norucholic acid. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Signed informed consent, • Male or female patients ≥ 18 and ≤ 74 years at screening, • PBC verified by at least 2 out of the following 3 criteria at screening: - Chronic cholestatic disease of at least 12 months duration, - Positive anti-mitochondrial antibody (AMA) titer or, if AMA negative or in low titer (< 1:80), presence of PBC-specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex]), - Liver biopsy available for review and compatible with the diagnosis of non-cirrhotic PBC, • Ursodeoxycholic acid (UDCA) treatment for at least 12 months (with a stable dose for ≥ 3 months) prior to screening, • Women of childbearing potential agreeing to use a highly effective method of birth control during the entire duration of the trial and for 4 weeks following the last dose of trial treatment, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptive methods, some intrauterine devices (IUD), sexual abstinence, or vasectomized partner. Women of non-childbearing potential (surgically sterile [e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy], or postmenopausal with at least two years without spontaneous menses) may be included. The investigator is responsible for determining whether the patient has adequate birth control for trial participation.
|
|
E.4 | Principal exclusion criteria |
• History or presence of any other relevant concomitant liver diseases. • Patients taking prohibited medications • Liver cirrhosis. NOTE: Patients with compensated cirrhosis and a Child-Pugh Score <8 are allowed to participate, • Any known relevant infectious disease (e.g., active tuberculosis, acquired immunodeficiency syndrome [AIDS]-defining diseases), • Abnormal renal function (glomerular filtration rate estimated from cystatin C < 30 ml/min) at screening visit, • Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell carcinoma, or any cancer curatively treated < 3 years before screening, • Existing or intended pregnancy or breast-feeding
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Mean relative change (%) in ALP between the baseline visit and the EOT visit (Last Observation Carried Forward, LOCF). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
End of Treatment, 12 weeks after baseline |
|
E.5.2 | Secondary end point(s) |
1. Proportions of patients with at least 10%, at least 20%, and at least 40% reduction in ALP between baseline and End of treatment (LOCF), 2. Proportion of patients with normalisation of ALP (< ULN) at any visit during the treatment phase, 3. Proportion of patients with bilirubin levels <0.6x ULN at any visit during the treatment phase, 4. Proportion of patients with partial normalisation of ALP (< 1.5x ULN) at any visit during the treatment phase, 5. ALP at each trial visit (screening to follow-up), 6. Absolute and relative changes (%) of ALP from baseline to each visit up to End of treatment (LOCF), and from End of treatment to the follow-up visit, 7. Gamma-glutamyltransferase (γ-GT), AST, ALT, albumin, platelet count and total and conjugated bilirubin levels at each trial visit (screening to follow-up), 8. Absolute and relative changes (%) of γ-GT, AST, ALT, albumin, platelet count and total and conjugated bilirubin levels from baseline to each visit up to End of treatment (LOCF), and from End of treatment to the follow-up visit.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. End of Treatment, 12 weeks after baseline 2. any visit during the treatment phase 3. any visit during the treatment phase 4. any visit during the treatment phase 5. at each trial visit 6. End of treatment and follow-up visit 7. at each trial visit 8. End of treatment and follow-up visit |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
two different doses of IMP: 1500mg/d and 1000mg/d NCA |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 43 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Switzerland |
United Kingdom |
Austria |
Belgium |
Denmark |
Finland |
France |
Germany |
Netherlands |
Norway |
Poland |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |